

INDEX

LIST OF ABBREVIATIONS	XXIII
LIST OF FIGURES.....	XXVII
LIST OF TABLES.....	XXXI
I. INTRODUCTION.....	1
1. CANCER.....	3
1.1. CONCEPT	3
1.2. MOLECULAR BIOLOGY	3
2. LUNG CANCER.....	6
2.1. EPIDEMIOLOGY.....	6
2.2. ETIOLOGY	7
2.3. DIAGNOSIS AND PROGNOSIS	8
2.4. HISTOLOGICAL CLASSIFICATION	11
2.5. MOLECULAR CLASSIFICATION	13
2.6. TREATMENT.....	16
3. CANCER STEM CELLS	18
3.1. TUMOR HETEROGENEITY	18
3.2. PROPERTIES	21
3.3. <i>IN VITRO</i> CULTURE.....	24
3.4. MARKERS.....	26
3.5. SIGNALING PATHWAYS.....	30
3.5.1. Notch signaling pathway	31
3.5.2. Wnt signaling pathway.....	35
3.5.3. Hedgehog signaling pathway.....	39
3.5.4. Other signaling pathways.....	42

IV. RESULTS & DISCUSSION 73

1. ESTABLISHMENT OF ADHERENT AND NON-ADHERENT CULTURES....	75
1.1. PHENOTYPIC CHARACTERIZATION OF PRIMARY CULTURES.....	81
1.1.1. SELF-RENEWAL, PROLIFERATION AND DIFFERENTIATION CAPACITIES	81
1.1.2. INVASION AND TUMOR INITIATION CAPACITIES.....	83
1.1.3. RESISTANCE TO CLASSICAL CHEMOTHERAPEUTIC AGENTS.	85
2. GENE EXPRESSION ANALYSIS.....	87
2.1. RNA QUANTIFICATION AND QUALITY ASSESSEMENT	87
2.2. RELATIVE mRNAs EXPRESSION	88
2.3. UNSUPERVISED PRINCIPALCOMPONENTS ANALYSIS.....	93
3. PROTEIN EXPRESSION ANALYSIS	99
3.1. IMMUNOBLOTTING	99
3.2. IMMUNOFLUORESCENCE.....	102
3.1. IMMUNOHISTOCHEMISTRY	106
4. <i>IN SILICO</i> SURVIVAL ANALYSIS	108
4.1. CLINICOPATHOLOGICAL VARIABLES	108
4.2. INDIVIDUAL BIOMARKERS.....	113
4.3. GENE EXPRESSION SCORE	120
4.4. MULTIVARIATE ANALYSIS.....	122
5. VALIDATION OF THE PROGNOSTIC GENE EXPRESSION SCORE	124
5.1. CLINICOPATHOLOGICAL VARIABLES	124
5.2. INDIVIDUAL BIOMARKERS.....	130
5.3. GENE EXPRESSION SCORE	131
6. PHARMACOLOGICAL INHIBITION OF CSCs POTENTIAL TARGETS	133
7. INTEGRATION OF RESULTS	135

V. CONCLUSIONS.....	139
VI. REFERENCES.....	143
VII. APPENDICES.....	179
1. SUPPLEMENTARY MATERIAL	181
2. APPROVAL FROM THE INSTITUTIONAL ETHICAL AND SCIENTIFIC REVIEW BOARD	183
3. FUNDING	185
4. NATIONAL AND INTERNATIONAL CONGRESS COMMUNICATIONS .	185
5. PUBLICATIONS	190
6. AWARDS	190